Prognostic characteristics of T-cell mediated cell killing-related genes in lung adenocarcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):1–12.
   Web of Science ®Google Scholar
• Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32(4):669–692.
   PubMed Web of Science ®Google Scholar
• Miller KD, Goding Sauer A, Ortiz AP, et al. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(6):425–445.
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Pardoll DM. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;379(9):e14.
   PubMedGoogle Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148.
   PubMed Web of Science ®Google Scholar
• Hong WF, Liu MY, Liang L, et al. Molecular characteristics of T cell-mediated tumor killing in hepatocellular carcinoma. Front Immunol. 2022;13:868480.
   PubMed Web of Science ®Google Scholar
• Kim A, Han CJ, Driver I, et al. LILRB1 blockade enhances bispecific T cell engager antibody-induced tumor cell killing by effector CD8(+) T cells. J Immunol. 2019;203(4):1076–1087.
   PubMed Web of Science ®Google Scholar
• Aschmoneit N, Steinlein S, Kuhl L, et al. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. Sci Rep. 2021;11(1):13880.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.
   PubMed Web of Science ®Google Scholar
• Flynn R. Survival analysis. J Clin Nurs. 2012;21(19-20):2789–2797.
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
   PubMed Web of Science ®Google Scholar
• Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381–5397.
   PubMed Web of Science ®Google Scholar
• Huang C, Liu Z, Xiao L, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and fibrinogen-to-lymphocyte ratio in gastric cancer with peritoneal dissemination. Front Oncol. 2019;9:1159.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262.
   PubMed Web of Science ®Google Scholar
• Skidmore ZL, Wagner AH, Lesurf R, et al. GenVisR: genomic visualizations in R. Bioinformatics. 2016;32(19):3012–3014.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Goding Sauer A, et al. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–164.
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129.
   PubMed Web of Science ®Google Scholar
• Yi M, Qin S, Zhao W, et al. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol. 2018;7:28.
   PubMed Web of Science ®Google Scholar
• Liu L, Yang S, Lin K, et al. Sp1 induced gene TIMP1 is related to immune cell infiltration in glioblastoma. Sci Rep. 2022;12(1):11181.
   PubMed Web of Science ®Google Scholar
• Meng C, Yin X, Liu J, et al. TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: a meta-analysis. PLoS One. 2018;13(11):e0207039.
   PubMed Web of Science ®Google Scholar
• D'Costa Z, Jones K, Azad A, et al. Gemcitabine-induced TIMP1 attenuates therapy response and promotes tumor growth and liver metastasis in pancreatic cancer. Cancer Res. 2017;77(21):5952–5962.
   PubMed Web of Science ®Google Scholar
• Shou Y, Liu Y, Xu J, et al. TIMP1 indicates poor prognosis of renal cell carcinoma and accelerates tumorigenesis via EMT signaling pathway. Front Genet. 2022;13:648134.
   PubMed Web of Science ®Google Scholar
• Ma B, Ueda H, Okamoto K, et al. TIMP1 promotes cell proliferation and invasion capability of right-sided Colon cancers via the FAK/akt signaling pathway. Cancer Sci. 2022;113(12):4244–4257.
   PubMed Web of Science ®Google Scholar
• Zeng WJ, Yang YL, Wen ZP, et al. Identification of gene expression and DNA methylation of SERPINA5 and TIMP1 as novel prognostic markers in lower-grade gliomas. PeerJ. 2020;8:e9262.
   PubMed Web of Science ®Google Scholar
• Luo L, Li M, Su J, et al. FURIN correlated with immune infiltration serves as a potential biomarker in SARS-CoV-2 infection-related lung adenocarcinoma. Clin Exp Med. 2022;22(3):371–384.
   PubMed Web of Science ®Google Scholar
• Ma YC, Fan WJ, Rao SM, et al. Effect of Furin inhibitor on lung adenocarcinoma cell growth and metastasis. Cancer Cell Int. 2014;14:43.
   PubMed Web of Science ®Google Scholar
• Debreova M, Csaderova L, Burikova M, et al. CAIX regulates invadopodia formation through both a pH-dependent mechanism and interplay with actin regulatory proteins. Int J Mol Sci. 2019;20(11):2745.
   PubMed Web of Science ®Google Scholar
• Yin L, Lu Y, Cao C, et al. CA9-related acidic microenvironment mediates CD8+ T cell related immunosuppression in pancreatic cancer. Front Oncol. 2021;11:832315.
   PubMed Web of Science ®Google Scholar
• Sung HY, Ju W, Ahn JH. DNA hypomethylation-mediated overexpression of carbonic anhydrase 9 induces an aggressive phenotype in ovarian cancer cells. Yonsei Med J. 2014;55(6):1656–1663.
   PubMed Web of Science ®Google Scholar
• Afsharpad M, Nowroozi MR, Mobasheri MB, et al. Cancer-testis antigens as new candidate diagnostic biomarkers for transitional cell carcinoma of bladder. Pathol Oncol Res. 2019;25(1):191–199.
   PubMed Web of Science ®Google Scholar
• Chun HK, Chung KS, Kim HC, et al. OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers. BMB Rep. 2010;43(5):349–354.
   PubMed Web of Science ®Google Scholar
• Chen L, Wang R, Gao L, et al. Opa-interacting protein 5 expression in human glioma tissues is essential to the biological function of U251 human malignant glioma cells. Cancer Control. 2020;27(1):1073274820968914.
   Web of Science ®Google Scholar
• Konner AC, Bruning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab. 2011;22(1):16–23.
   PubMed Web of Science ®Google Scholar
• Fan Y, Yang L, Wei Q, et al. Toll-like receptor 10 (TLR10) exhibits suppressive effects on inflammation of prostate epithelial cells. Asian J Androl. 2019;21(4):393–399.
   PubMed Web of Science ®Google Scholar
• Bohni PC, Deshaies RJ, Schekman RW. SEC11 is required for signal peptide processing and yeast cell growth. J Cell Biol. 1988;106(4):1035–1042.
   PubMed Web of Science ®Google Scholar
• Wang S, He Z, Wang X, et al. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife. 2019;8:e49020.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501.
   PubMed Web of Science ®Google Scholar
• Yi M, Li A, Zhou L, et al. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma. Cancer Immunol Immunother. 2021;70(6):1705–1719.
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, et al. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173.
   PubMed Web of Science ®Google Scholar
• McGrail DJ, Pilie PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–672.
   PubMed Web of Science ®Google Scholar
• Amin M, Desai M, Trinkaus K, et al. Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. J Gastrointest Oncol. 2019;10(3):412–420.
   PubMed Web of Science ®Google Scholar
• Illiano M, Sapio L, Salzillo A, et al. Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via protein kinase A-mediated ERK1/2 inhibition. Biochem Pharmacol. 2018;152:104–113.
   PubMed Web of Science ®Google Scholar